Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New nasal spray could ease COVID-19 symptoms

NCT ID NCT05799521

First seen Nov 01, 2025 · Last updated May 22, 2026 · Updated 35 times

Summary

This study tests a new inhaled medication called Optate for people with mild COVID-19. About 40 adults will receive either Optate or a placebo spray. Researchers will measure virus levels in the nose and track symptom changes using a quality-of-life survey. The goal is to see if Optate can safely reduce symptoms and lower the amount of virus.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COVID-19 are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Riley Hospital for Children

    RECRUITING

    Indianapolis, Indiana, 46202, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.